Q3FY2025 Performance Highlights Revenue at ₹11,537m, grew 14.6% YoY Gross margin at ₹6,735m, grew 25.1% YoY EBITDA grew 46.9% YoY to ₹2,103m with EBITDA margin at 18.2%, grew 401bps YoY US revenue at $73m, grew 13.7% YoY Q3FY25 Reported PAT at ₹900m Reported
Q1FY2025 Performance Highlights Revenues at ₹10,875m, Grew 16.7% YoY in line with FY25 Outlook Gross Margin improved by 264bps YoY to 61.3% EBITDA grew by 28.7% YoY to ₹2,170m with EBITDA margin at 20%, a growth of 187bps YoY US revenues at a historic
FY2024 Performance Highlights Highest ever full-year Revenue of ₹40,555 million in FY24, up 14.4% YoY Highest ever full-year EBITDA of ₹7,477 million in FY24, up 77.6% YoY US business achieved top end of $250 million revenue outlook for FY24, grew by 11.8% YoY Net
These Powered Air Purifying Respirator (PAPR) kits are superior to regular PPEs being low cost, low weight and having higher flow. A usability study with 20 PAPR kits is underway In what could be termed as the first ever made in India, Powered Air Purifying Respirator (PAPR) kits, doctors at
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
